SeraNovo
{{subst:submit}}
| Private | |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | 2017 |
| Founders 👔 | Niall Hodgins; Ian Degeling |
| Headquarters 🏙️ | Leiden, Netherlands |
Area served 🗺️ | |
| Products 📟 | Drug formulation technologies |
| Members | |
Number of employees | |
| 🌐 Website | seranovo |
| 📇 Address | |
| 📞 telephone | |
SeraNovo is a biotechnology company based in Leiden, Netherlands, that develops formulation technologies for oral drug delivery.[1][2] The company operates within the Leiden Bio Science Park, a major Dutch life sciences cluster.[3]
History
SeraNovo was founded in 2017 in Leiden.[3] In 2018, it won the LifeSciences@Work Venture Challenge at the Dutch Life Sciences Conference.[4] In 2019, SeraNovo received funding from the UNIIQ proof-of-concept fund, a regional investment program.[5]
Technology
A large proportion of drug candidates discovered in modern pharmaceutical research have low aqueous solubility or low permeability, which limits their oral bioavailability.[6] This challenge has been reported as a major cause of late-stage drug development failure.[7]
Peer-reviewed reviews describe approaches such as amorphous solid dispersions and lipid-based systems to improve oral drug absorption.[8]
Trade publications report that SeraNovo has developed a platform, called NanoGlass, which uses solid dispersion techniques to stabilize drugs in an amorphous state and increase dissolution rates.[9]
Coverage in Pharmaceutical Technology notes that the platform has been applied to small molecules and emerging therapeutic modalities such as protein degraders and peptides.[10]
The company is also reported to provide preformulation screening, prototype development, and stability testing services.[11]
Collaborations and partnerships
In 2020, SeraNovo signed a second license agreement with Carna Biosciences to develop an oral formulation of a kinase inhibitor.[12][13]
In 2022, the company entered into a second agreement with Graviton Bioscience[14] and signed a multi-compound agreement with Ildong Pharmaceutical, a South Korean company.[15]
SeraNovo has also collaborated with Gattefossé to present webinars on lipid-based formulation approaches.[16]
In 2023, AstraZeneca and SeraNovo announced a multi-compound collaboration to apply SeraNovo’s formulation platform across selected drug candidates.[1][2]
Recognition
SeraNovo’s award at the LS@W Venture Challenge and its receipt of UNIIQ funding have been reported by Dutch life sciences organizations.[4][5] Coverage of its partnerships has appeared in trade publications including Pharmaceutical Technology and Contract Pharma.[2]
See also
References
- ↑ 1.0 1.1 Murphy, Jill (17 May 2023). "SeraNovo and AstraZeneca to collaborate on research projects". Manufacturing Chemist. Retrieved 22 September 2025.
- ↑ 2.0 2.1 2.2 Brooks, Kristin (17 May 2023). "SeraNovo, AstraZeneca Close Multi-Compound Deal". Contract Pharma. Retrieved 22 September 2025.
- ↑ 3.0 3.1 "SeraNovo is Solving the Problem of Drug Solubility". PLNT Leiden. 10 October 2023. Retrieved 22 September 2025.
- ↑ 4.0 4.1 "SeraNovo wins the 20th edition of the LS@W Venture Challenge". Dutch Life Sciences Conference. 29 November 2018. Retrieved 22 September 2025.
- ↑ 5.0 5.1 "Venture Challenge Fall 2018 winner SeraNovo receives UNIIQ investment". Health~Holland. February 2019. Retrieved 22 September 2025.
- ↑ Losada-Barreiro, S.; Celik, S. (2024). "Carrier Systems for Advanced Drug Delivery: Improving Drug Solubility/Bioavailability and Administration Routes". Pharmaceutics. 16 (7): 852. doi:10.3390/pharmaceutics16070852. PMC 11279846 Check
|pmc=value (help). PMID 39065549 Check|pmid=value (help). - ↑ Lipinski, C. A. (2000). "Drug-like properties and the causes of poor solubility and poor permeability". Journal of Pharmacological and Toxicological Methods. 44 (1): 235–249. doi:10.1016/S1056-8719(00)00107-6. PMID 11274893.
- ↑ Savjani, K. T.; Gajjar, A. K.; Savjani, J. K. (2012). "Drug Solubility: Importance and Enhancement Techniques". ISRN Pharmaceutics. 2012: 1–10. doi:10.5402/2012/195727. PMC 3399483. PMID 22830056.
- ↑ "SeraNovo Enters Second License Agreement With Carna Biosciences". Drug Development & Delivery. 26 May 2020. Retrieved 22 September 2025.
- ↑ Murphy, Jill (17 May 2023). "SeraNovo and AstraZeneca Collaborate on Future Research Projects". BioPharm International. Retrieved 22 September 2025.
- ↑ "SeraNovo is Solving the Problem of Drug Solubility". PLNT Leiden. 10 October 2023. Retrieved 22 September 2025.
- ↑ "SeraNovo Enters Second License Agreement With Carna Biosciences". Drug Development & Delivery. 26 May 2020. Retrieved 22 September 2025.
- ↑ "SeraNovo Enters Into License Agreement with Carna Biosciences for Development of Oral Formulation". Pharma’s Almanac. Retrieved 22 September 2025.
- ↑ "SeraNovo and Graviton deepen collaboration and enter into a second license agreement". LifeSciences@Work. 5 January 2022. Retrieved 22 September 2025.
- ↑ "SeraNovo and Ildong Pharmaceutical to collaborate on research projects". LifeSciences@Work. 26 September 2022. Retrieved 22 September 2025.
- ↑ "Webinar Series: Gattefossé and SeraNovo". PharmaExcipients. 31 March 2025. Retrieved 22 September 2025.
External links
This article "SeraNovo" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:SeraNovo. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
